A monensin premix and a method for preparing the same

Abstract

The application relates to the technical field of feed additives, and discloses a monensin premix and a preparation method thereof.The raw material composition of the monensin premix comprises monensin, a carrier, a surfactant, a binder, amino acid chelated trace elements, vitamin E, ascorbic acid palmitate and coenzyme Q10.The preparation method comprises the following steps: S1, stirring and mixing monensin and the carrier to prepare a mixture I; S2, dissolving the binder in a water bath at 80-100 DEG C, cooling to room temperature, adding the mixture I and the remaining raw materials, and stirring and mixing to prepare a mixture II; S3, uniformly treating the mixture II to prepare an intermediate product; and S4, preparing the intermediate product into granules by using a spray drying method, so that the monensin premix is obtained.The monensin premix prepared by the application is uniform in granularity, good in stability and uniformity, and high in drug efficacy.

Description

Technical Field

[0001] This application relates to the field of feed additive technology, and in particular to a monensin premix and its preparation method. Background Technology

[0002] Monensin, also known as "rumen extract," is a widely used feed additive for ruminants. It was originally a substance secreted by Streptomyces. Monensin's main functions are to control the proportion of volatile fatty acids in the rumen, reduce protein degradation, decrease feed dry matter consumption, improve nutrient utilization, and enhance the animal's energy efficiency.

[0003] Monensin premix is ​​a feed additive containing monensin. This premix is ​​mainly used to promote the growth of ruminants and prevent coccidiosis in chickens.

[0004] Monensin premix can regulate the rumen environment, improve feed digestibility and utilization, thereby increasing animal weight gain. Monensin premix also has anticoccidial activity, effectively preventing and treating coccidiosis in chickens.

[0005] Early monensin premixes, once developed, showed significant effects in promoting animal growth and improving feed utilization. However, due to limitations in production processes and technology, the cost of preparing early monensin premixes was high, limiting their widespread application. Later, by changing the formulation and production process, manufacturing costs were reduced. However, the formulations exhibited poor stability, were easily affected by environmental factors and became ineffective, and had low bioavailability.

[0006] Currently, the performance and quality of monensin premixes are continuously improving, and their application range is expanding, meeting diverse market demands. However, uneven mixing can occur during feed mixing, affecting livestock and poultry feed intake and the efficacy of the drug. The stability and uniformity of monensin premixes still need improvement.

[0007] Therefore, there is an urgent need to develop a monensin premix with uniform particle size, good stability and uniformity, and strong efficacy. Summary of the Invention

[0008] In order to solve at least one of the above-mentioned technical problems and to develop a monensin premix with uniform particle size, good stability and uniformity, and strong efficacy, this application provides a monensin premix and its preparation method.

[0009] On the one hand, the monensin premix provided in this application comprises, by weight, 10-20 parts of monensin, 50-80 parts of carrier, 5-10 parts of surfactant, 2-6 parts of binder, 0.3-1 parts of amino acid chelated trace elements, 0.1-0.2 parts of vitamin E, 0.1-0.2 parts of ascorbate palmitate, and 0.1-0.2 parts of coenzyme Q10.

[0010] By adopting the above technical solution, this application uses specific raw materials and proportions to prepare a monensin premix with uniform particle size, good stability and uniformity, and strong efficacy.

[0011] The inclusion of a binder in this application allows the components of the monensin premix to adhere better together, reducing component separation and precipitation, thereby improving the stability of the monensin premix. It also improves the flowability of the premix and controls the release rate of the monensin premix, thus regulating its efficacy in animals.

[0012] This application incorporates amino acid chelated trace elements, which can protect trace elements from interference by other substances in the environment, maintain their activity for a longer period in monensin premixes, and improve the bioavailability of trace elements. It can also improve feed palatability, increase animal feed intake, and promote animal growth and development.

[0013] This application incorporates vitamin E, ascorbate palmitate, and coenzyme Q10, which have antioxidant effects, extend shelf life, enhance animal immune function, improve resistance to disease, and promote animal growth and development.

[0014] Optionally, the carrier is selected from at least one of sodium sulfate, calcium phosphate, glucose, and starch.

[0015] By adopting the above technical solution, this application selects at least one of sodium sulfate, calcium phosphate, glucose, and starch as the carrier of monensin. Sodium sulfate can also regulate pH and increase product stability. Calcium phosphate can also provide phosphorus, promote animal growth and development, and improve product stability. Glucose also has antioxidant properties. Starch can also improve the adhesion and flowability of the product.

[0016] Optionally, the average particle size of the carrier is 80–150 μm.

[0017] By adopting the above technical solution, the average particle size of the carrier in this application is 80–150 μm, which helps to improve the dispersibility and uniformity of the monensin premix. A suitable particle size also helps to improve the product's flowability, facilitating transportation and use. If the carrier particle size is too large, the distribution of monensin will be uneven, while if the carrier particle size is too small, excessive monensin may be adsorbed onto the carrier surface, also affecting its uniformity.

[0018] Optionally, the average particle size of the carrier is 110 μm.

[0019] Optionally, the surfactant is selected from at least one of sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, and fatty alcohol polyoxyethylene ether.

[0020] By adopting the above technical solution, surfactants can reduce surface tension and enhance dispersibility, thereby contributing to the uniform dispersion and stable storage of monensin premix.

[0021] Optionally, the adhesive is selected from at least one of gum arabic, astragalus gum, and peach gum.

[0022] By adopting the above technical solution, the adhesive of this application has good adhesion and film-forming properties, which can improve the stability and flowability of monensin premix, and play an important role in ensuring the quality and efficacy of monensin premix.

[0023] Optionally, the adhesive is astragalus gum and peach gum, wherein the weight ratio of astragalus gum and peach gum is 1:1.

[0024] By adopting the above technical solution, both astragalus gum and peach gum in this application are natural plant gums with good safety and environmental friendliness, making them suitable for animal feed production. Furthermore, the simultaneous use of astragalus gum and peach gum allows for mutual adsorption, potentially exhibiting unique adhesive and rheological properties, which helps improve the stability and flowability of the monensin premix.

[0025] Optionally, the amino acid chelated trace elements include amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese, wherein the weight ratio of amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese is 1:1:2-3.

[0026] By adopting the above technical solutions, the amino acid chelated trace element formulation in this application can provide more comprehensive and balanced nutritional elements to meet the needs of animal growth and development. At the same time, amino acid chelation technology can also improve the bioavailability and stability of trace elements, reduce their interaction with other substances, and improve the efficacy and quality of monensin premix.

[0027] Optionally, the weight ratio of the amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese is 1:1:2.

[0028] Optionally, the weight ratio of the amino acid chelated trace element to the coenzyme Q10 is 3 to 5:1.

[0029] By employing the above-mentioned technical solutions, amino acid chelation with trace elements can increase the stability of coenzyme Q10 and improve its antioxidant properties. Specific ratios can enhance their stability and compatibility.

[0030] Optionally, the weight ratio of the amino acid chelated trace element to the coenzyme Q10 is 4:1.

[0031] Secondly, this application provides a method for preparing the above-mentioned monensin premix, comprising the following steps:

[0032] S1. Mix the monensin and the carrier to obtain mixture I;

[0033] S2. Dissolve the adhesive in a water bath at 80-100°C, cool to room temperature, add the mixture I, the surfactant, the amino acid chelated trace elements, the vitamin E, the ascorbate palmitate, and the coenzyme Q10, stir and mix to obtain mixture II;

[0034] S3. Homogenize mixture II to obtain an intermediate product;

[0035] S4. The intermediate product is made into granules by spray drying, which is the monensin premix.

[0036] By adopting the above technical solution, this application obtains a monensin premix with uniform particle size, good stability and uniformity, and strong efficacy by controlling the proportion of various raw materials and processing technology. The mixing in step S1 ensures uniform distribution of monensin on the carrier, laying the foundation for further mixing. Step S2 enables thorough mixing of various components, improving the quality and efficacy of the monensin premix. Homogenization treatment improves the stability and flowability of the monensin premix. Finally, rapid drying using spray drying maintains the product's quality and efficacy.

[0037] Optionally, in step S2, the stirring speed is 100-200 rpm and the stirring time is 30-60 min.

[0038] By adopting the above technical solution, this application uses specific stirring speeds and times to ensure the stability and uniformity of the monensin premix. If the stirring speed is too fast or the stirring time is too long, the active ingredients may be destroyed or volatilized; if the stirring speed is too slow or the stirring time is too short, the mixture may not be fully mixed, resulting in unevenness. This affects the stability and uniformity of the monensin premix.

[0039] Optionally, in step S2, the stirring speed is 150 rpm and the stirring time is 45 min.

[0040] Optionally, in step S3, the rotation speed of the homogenization process is 500-1500 rpm, and the processing time is 15-30 min.

[0041] By adopting the above technical solution, this application sets the rotation speed and processing time for homogenization to ensure the stability and uniformity of the product. If the rotation speed is too high, excessive heat may be generated, affecting product quality; if the rotation speed is too low, the homogenization effect may be poor, resulting in an uneven product. If the processing time is too long, the product may be over-homogenized, destroying the effective components; if the processing time is too short, the homogenization effect may be poor, resulting in an uneven product.

[0042] Optionally, the homogenization process is performed at a rotation speed of 1000 rpm for a processing time of 20 min.

[0043] Optionally, in step S4, the spray drying conditions are: inlet air temperature of 120–150°C, drying temperature of 70–90°C, outlet air temperature of 50–70°C, and ventilation volume of 100–600 m³ / h. 3 / h.

[0044] By adopting the above technical solution, this application employs specific spray drying conditions to obtain a monensin premix with good stability and efficacy. Excessively high inlet air temperature may cause the active ingredients in the product to volatilize or decompose, while excessively low inlet air temperature may affect the drying speed. Excessively high drying temperature and outlet air temperature may lead to over-drying of the product, while excessively low drying temperature and outlet air temperature may affect the drying effect. Ventilation volume affects both drying efficiency and drying effect.

[0045] Optionally, the spray drying conditions are: inlet air temperature of 140℃, drying temperature of 80℃, outlet air temperature of 60℃, and ventilation volume of 400m³. 3 / h.

[0046] In summary, the present invention has at least one of the following beneficial technical effects:

[0047] 1. This application uses specific raw materials and proportions to prepare a monensin premix with uniform particle size, good stability and uniformity, and strong efficacy.

[0048] 2. The addition of a binder in this application can reduce the separation and precipitation of components, thereby improving the stability of the monensin premix.

[0049] 3. By controlling the proportions of various raw materials and processing techniques, this application can ensure the stability, uniformity, and efficacy of monensin premix. Detailed Implementation

[0050] The present application will be further described in detail below with reference to the embodiments.

[0051] This application designs a monensin premix, which, by weight, comprises: 10-20 parts monensin, 50-80 parts carrier, 5-10 parts surfactant, 2-6 parts binder, 0.3-1 parts amino acid chelated trace elements, 0.1-0.2 parts vitamin E, 0.1-0.2 parts ascorbate palmitate, and 0.1-0.2 parts coenzyme Q10.

[0052] The monensin premix of this application is prepared by the following method, including the following steps: S1, stirring and mixing the monensin and the carrier to obtain mixture I;

[0053] S2. Dissolve the adhesive in a water bath at 80-100°C, cool to room temperature, add the mixture I, the surfactant, the amino acid chelated trace elements, the vitamin E, the ascorbate palmitate, and the coenzyme Q10, stir and mix to obtain mixture II;

[0054] S3. Homogenize mixture II to obtain an intermediate product;

[0055] S4. The intermediate product is made into granules by spray drying, which is the monensin premix.

[0056] This application addresses the problems of poor stability and uniformity, and low bioavailability of existing monensin premixes by designing the technical solution described herein.

[0057] This application first presents a monensin premix, comprising: monensin, a carrier, a surfactant, a binder, amino acid chelated trace elements, vitamin E, ascorbate palmitate, and coenzyme Q10. The prepared monensin premix exhibits uniform particle size, good stability and uniformity, and strong efficacy.

[0058] Secondly, the preparation method of monensin premix adopted in this application can ensure the stability, uniformity and efficacy of monensin premix by controlling the proportion of various raw materials and processing technology, thereby ensuring the healthy growth of animals.

[0059] The raw materials used in this application are as follows:

[0060] Monensin: CAS: 17090-79-8.

[0061] Sodium sulfate: CAS: 7757-82-6.

[0062] Calcium phosphate: CAS: 10103-46-5.

[0063] Glucose: CAS: 58367-01-4.

[0064] Starch: CAS: 9005-25-8.

[0065] Sodium dodecyl sulfate: CAS: 151-21-3.

[0066] Sodium dodecylbenzenesulfonate: CAS: 25155-30-0.

[0067] Fatty alcohol polyoxyethylene ether: Chengdu Huaxia Chemical Reagent Co., Ltd., purity: 99% HPLC.

[0068] Gum arabic: CAS: 9000-01-5.

[0069] Astragalus gum: CAS: 9000-65-1.

[0070] Peach gum: Fujian Shengshi Jiatai Biotechnology Co., Ltd.

[0071] Amino acid chelated zinc: Fujian Shengshi Jiatai Biotechnology Co., Ltd.

[0072] Amino acid chelated copper: Taian Jiayue Biochemical Co., Ltd.

[0073] Amino acid chelated manganese: Wuhan Huajiu Pharmaceutical Technology Co., Ltd.

[0074] Vitamin E: CAS: 2074-53-5.

[0075] Ascorbyl palmitate: CAS: 137-66-6.

[0076] Coenzyme Q10: CAS: 303-98-0. Specific Implementation

[0078] Examples 1-4

[0079] Example 1

[0080] This embodiment provides a monensin premix, the raw material composition of which includes: 10 parts monensin, 60 parts sodium sulfate, 10 parts sodium dodecyl sulfate, 5 parts gum arabic, 0.3 parts amino acid chelated trace elements, 0.2 parts vitamin E, 0.12 parts ascorbate palmitate, and 0.1 parts coenzyme Q10. The amino acid chelated trace elements consist of amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese in a weight ratio of 1:1:2. The average particle size of the sodium sulfate is 80 μm.

[0081] The preparation method of monensin premix includes the following steps:

[0082] S1. Mix monensin and sodium sulfate to prepare mixture I;

[0083] S2. Dissolve gum arabic in a water bath at 90°C, cool to room temperature, add mixture I, sodium dodecyl sulfate, amino acid chelated trace elements, vitamin E, ascorbate palmitate and coenzyme Q10, stir and mix at 150 rpm for 45 min to obtain mixture II.

[0084] S3. Homogenize mixture II to obtain an intermediate product. The homogenization speed is 1000 rpm and the processing time is 20 min.

[0085] S4. The intermediate product is granulated using spray drying to obtain monensin premix. The spray drying conditions are: inlet air temperature 140℃, drying temperature 80℃, outlet air temperature 60℃, and ventilation volume 400m³. 3 / h.

[0086] Example 2

[0087] This embodiment provides a monensin premix, the raw material composition of which includes: 16 parts monensin, 70 parts sodium sulfate, 8 parts sodium dodecyl sulfate, 4 parts gum arabic, 0.5 parts amino acid chelated trace elements, 0.15 parts vitamin E, 0.15 parts ascorbate palmitate, and 0.12 parts coenzyme Q10. The amino acid chelated trace elements consist of amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese in a weight ratio of 1:1:2. The average particle size of the sodium sulfate is 80 μm.

[0088] The preparation method of monensin premix includes the following steps:

[0089] S1. Mix monensin and sodium sulfate to prepare mixture I;

[0090] S2. Dissolve gum arabic in a water bath at 90°C, cool to room temperature, add mixture I, sodium dodecyl sulfate, amino acid chelated trace elements, vitamin E, ascorbate palmitate and coenzyme Q10, stir and mix at 150 rpm for 45 min to obtain mixture II.

[0091] S3. Homogenize mixture II to obtain an intermediate product. The homogenization speed is 1000 rpm and the processing time is 20 min.

[0092] S4. The intermediate product is granulated using spray drying to obtain monensin premix. The spray drying conditions are: inlet air temperature 140℃, drying temperature 80℃, outlet air temperature 60℃, and ventilation volume 400m³. 3 / h.

[0093] Example 3

[0094] This embodiment provides a monensin premix, the raw material composition of which includes: 12 parts monensin, 50 parts sodium sulfate, 6 parts sodium dodecyl sulfate, 2 parts gum arabic, 1 part amino acid chelated trace elements, 0.12 parts vitamin E, 0.1 parts ascorbate palmitate, and 0.15 parts coenzyme Q10. The amino acid chelated trace elements consist of amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese in a weight ratio of 1:1:2. The average particle size of the sodium sulfate is 80 μm.

[0095] The preparation method of monensin premix includes the following steps:

[0096] S1. Mix monensin and sodium sulfate to prepare mixture I;

[0097] S2. Dissolve gum arabic in a water bath at 90°C, cool to room temperature, add mixture I, sodium dodecyl sulfate, amino acid chelated trace elements, vitamin E, ascorbate palmitate and coenzyme Q10, stir and mix at 150 rpm for 45 min to obtain mixture II.

[0098] S3. Homogenize mixture II to obtain an intermediate product. The homogenization speed is 1000 rpm and the processing time is 20 min.

[0099] S4. The intermediate product is granulated using spray drying to obtain monensin premix. The spray drying conditions are: inlet air temperature 140℃, drying temperature 80℃, outlet air temperature 60℃, and ventilation volume 400m³. 3 / h.

[0100] Example 4

[0101] This embodiment provides a monensin premix, the raw material composition of which includes: 20 parts monensin, 80 parts sodium sulfate, 5 parts sodium dodecyl sulfate, 6 parts gum arabic, 0.8 parts amino acid chelated trace elements, 0.1 parts vitamin E, 0.2 parts ascorbate palmitate, and 0.2 parts coenzyme Q10. The amino acid chelated trace elements consist of amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese in a weight ratio of 1:1:2. The average particle size of the sodium sulfate is 80 μm.

[0102] The preparation method of monensin premix includes the following steps:

[0103] S1. Mix monensin and sodium sulfate to prepare mixture I;

[0104] S2. Dissolve gum arabic in a water bath at 90°C, cool to room temperature, add mixture I, sodium dodecyl sulfate, amino acid chelated trace elements, vitamin E, ascorbate palmitate and coenzyme Q10, stir and mix at 150 rpm for 45 min to obtain mixture II.

[0105] S3. Homogenize mixture II to obtain an intermediate product. The homogenization speed is 1000 rpm and the processing time is 20 min.

[0106] S4. The intermediate product is granulated using spray drying to obtain monensin premix. The spray drying conditions are: inlet air temperature 140℃, drying temperature 80℃, outlet air temperature 60℃, and ventilation volume 400m³. 3 / h.

[0107] Comparative Examples 1-7

[0108] Comparative Example 1

[0109] The difference between Comparative Example 1 and Example 2 is that Comparative Example 1 does not contain gum arabic.

[0110] Comparative Example 2

[0111] The difference between Comparative Example 2 and Example 2 is that Comparative Example 2 does not contain ascorbyl palmitate.

[0112] Comparative Example 3

[0113] The difference between Comparative Example 3 and Example 2 is that in Comparative Example 3, the amino acid chelated trace elements were replaced with an equal amount of coenzyme Q10.

[0114] Comparative Example 4

[0115] The difference between Comparative Example 4 and Example 2 is that in Comparative Example 4, coenzyme Q10 was replaced with an equal amount of amino acid chelated trace elements.

[0116] Comparative Example 5

[0117] The difference between Comparative Example 5 and Example 2 is that Comparative Example 5 does not contain amino acid chelated trace elements and coenzyme Q10.

[0118] Comparative Example 6

[0119] The difference between Comparative Example 6 and Example 2 is that in Comparative Example 6, all raw materials were mixed at the same time, then homogenized and spray-dried.

[0120] Comparative Example 7

[0121] The difference between Comparative Example 7 and Example 2 is that Comparative Example 7 does not undergo homogenization treatment, but directly spray-dries the mixture II.

[0122] Experimental testing

[0123] Testing items and testing methods

[0124] Survival rate = (Number of live chickens / Total number of chickens) * 100%

[0125] Experiment dates: April 1, 2021 - May 12, 2021.

[0126] Experiment location: Weishi County, Kaifeng City, Henan Province.

[0127] 11,000 Ross 308 white-feathered broiler chickens were selected and divided into 11 groups. They were fed chicken feed, and monensin premix prepared in Examples 1-4 and Comparative Examples 1-7 were added to the feed of each group. The amount of monensin premix added was 300g / T. The survival rate of the chickens was recorded after 42 days.

[0128] The potency reduction rate of the monensin premixes prepared in Examples 1-4 and Comparative Examples 1-7 was tested, and the survival rate of chickens fed with feed containing the monensin premixes prepared in Examples 1-4 and Comparative Examples 1-7 was recorded. The test results are shown in Table 1.

[0129] Table 1

[0130]

[0131]

[0132] As shown in Table 1, the monensin premixes prepared in Examples 1-4 exhibited low potency reduction rates, indicating good uniformity and stability, significantly higher than those in Comparative Examples 1-7. Chickens fed with feed containing the monensin premixes prepared in Examples 1-4 showed significantly higher survival rates than those in Comparative Examples 1-7, demonstrating the strong efficacy and high bioavailability of the monensin premixes prepared in Examples 1-4.

[0133] Comparative Example 1 did not contain gum arabic, and Comparative Example 2 did not contain ascorbyl palmitate. The potency reduction rate of the monensin premix prepared in Comparative Example 1 and Comparative Example 2 increased sharply, and the uniformity and stability decreased significantly. Furthermore, the efficacy of the monensin premix prepared in Comparative Example 1 and Comparative Example 2 was also significantly reduced, as indicated by the chicken survival rate.

[0134] In Comparative Examples 3-5, the homogeneity, stability, and efficacy of the prepared monensin premixes were significantly reduced. Specifically, the potency reduction rate of the monensin premix prepared in Comparative Example 5 was significantly higher than that in Examples 3 and 4, and the chicken survival rate in Comparative Example 5 was also significantly lower than that in Examples 3 and 4. The applicant hypothesizes that amino acid-chelated trace elements interact with coenzyme Q10, and their simultaneous addition can enhance the homogeneity, stability, and efficacy of the monensin premixes.

[0135] Comparative Example 6 involved mixing all raw materials simultaneously, while Comparative Example 7 did not undergo a homogenization process. The resulting monensin premix exhibited inferior uniformity, stability, and efficacy compared to Example 2.

[0136] Example 5

[0137] The difference between Example 5 and Example 2 is that in Example 5, 70 parts of sodium sulfate are replaced with 20 parts of calcium phosphate, 20 parts of glucose and 30 parts of starch, and the particle size of the mixture of calcium phosphate, glucose and starch is 80 μm.

[0138] Example 6

[0139] The difference between Example 6 and Example 5 is that the particle size of the mixture of calcium phosphate, glucose and starch in Example 6 is 110 μm.

[0140] Example 7

[0141] The difference between Example 7 and Example 5 is that the particle size of the mixture of calcium phosphate, glucose and starch in Example 7 is 150 μm.

[0142] Example 8

[0143] The difference between Example 8 and Example 6 is that in Example 8, 10 parts of sodium dodecyl sulfate are replaced with 3 parts of sodium dodecyl sulfate, 3 parts of sodium dodecylbenzene sulfonate and 4 parts of fatty alcohol polyoxyethylene ether.

[0144] Example 9

[0145] The difference between Example 9 and Example 8 is that in Example 9, 5 parts of gum arabic are replaced with 2.5 parts of astragalus gum and 2.5 parts of...

[0146] Peach gum.

[0147] Example 10

[0148] The difference between Example 10 and Example 9 is that the amino acid chelated trace elements in Example 10 are amino acid chelated zinc, amino acid chelated copper and amino acid chelated manganese in a weight ratio of 1:1:3.

[0149] Example 11

[0150] The difference between Example 11 and Example 9 is that in Example 11, the total amount of amino acid chelated trace elements and coenzyme Q10 is 0.62 parts, and the weight ratio of amino acid chelated trace elements to coenzyme Q10 is 3:1.

[0151] Example 12

[0152] The difference between Example 12 and Example 9 is that in Example 12, the total amount of amino acid chelated trace elements and coenzyme Q10 is 0.62 parts, and the weight ratio of amino acid chelated trace elements to coenzyme Q10 is 5:1.

[0153] Example 13

[0154] The difference between Example 13 and Example 2 is that in step S2 of Example 13, the stirring speed is 100 rpm.

[0155] Example 14

[0156] The difference between Example 14 and Example 2 is that in step S2 of Example 14, the stirring speed is 200 rpm.

[0157] Example 15

[0158] The difference between Example 15 and Example 2 is that in step S3 of Example 15, the homogenization speed is 500 rpm.

[0159] Example 16

[0160] The difference between Example 16 and Example 2 is that in step S3 of Example 16, the homogenization speed is 1500 rpm.

[0161] Example 17

[0162] The difference between Example 17 and Example 2 is that in step S4 of Example 17, the air inlet temperature is 160°C.

[0163] Example 18

[0164] The difference between Example 18 and Example 2 is that in step S4 of Example 18, the drying temperature is 100°C.

[0165] Example 19

[0166] The difference between Example 19 and Example 2 is that in step S4 of Example 19, the outlet air temperature is 80°C.

[0167] 15,000 Ross 308 white-feathered broiler chickens were selected and divided into 15 groups. They were fed chicken feed, and each group's feed was supplemented with monensin premix prepared in Examples 5 to 19. The amount of monensin premix added was 300g / T. The survival rate of the chickens was recorded after 42 days.

[0168] The potency reduction rate of the monensin premixes prepared in Examples 5-19 was tested, and the survival rate of chickens fed with feed containing the monensin premixes prepared in Examples 5-19 was recorded. The test results are shown in Table 2.

[0169] Table 2

[0170]

[0171] As can be seen from the test results in Table 2, the monensin premix prepared by using a composite carrier in Example 5 has a low potency reduction rate and a high chicken survival rate. Therefore, the monensin premix has good uniformity and stability and strong efficacy.

[0172] The difference between Examples 5 to 7 is the average particle size of the carrier. Among them, the carrier particle size of Example 6 is 110 μm, and the resulting monensin premix has the best uniformity, stability and efficacy.

[0173] Example 8 uses a composite surfactant, and the resulting monensin premix has better uniformity, stability, and efficacy than that of Example 6.

[0174] Example 9 uses a composite adhesive. When astragalus gum and peach gum are added simultaneously, the uniformity, stability and efficacy of the monensin premix are improved.

[0175] The uniformity, stability and efficacy of the monensin premixes prepared in Examples 10-12 were not as good as those in Example 9.

[0176] In step S2 of Examples 13-14, the stirring speed is different; in step S3 of Examples 15-16, the homogenization speed is different; the inlet air temperature of Example 17 is higher; the drying temperature of Example 18 is higher; and the outlet air temperature of Example 19 is higher.

[0177] The uniformity, stability and efficacy of the monensin premixes prepared in Examples 13-19 were not as good as those in Example 2.

[0178] The above are all preferred embodiments of this application, and are not intended to limit the scope of protection of this application. Therefore, all equivalent changes made in accordance with the structure, shape and principle of this application should be covered within the scope of protection of this application.

Claims

1. A monensin premix, characterized in that, By weight, its raw material composition includes: 10-20 parts monensin, 50-80 parts carrier, 5-10 parts surfactant, 2-6 parts binder, 0.3-1 parts amino acid chelated trace elements, 0.1-0.2 parts vitamin E, 0.1-0.2 parts ascorbate palmitate, and 0.1-0.2 parts coenzyme Q10; The carrier is selected from at least one of sodium sulfate, calcium phosphate, glucose, and starch; The surfactant is selected from at least one of sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, and fatty alcohol polyoxyethylene ether; The adhesive is selected from at least one of gum arabic, astragalus gum, and peach gum; The amino acid chelated trace elements include amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese, and the weight ratio of amino acid chelated zinc, amino acid chelated copper, and amino acid chelated manganese is 1:1:2~3. The weight ratio of the amino acid chelated trace elements to the coenzyme Q10 is 3~5:1; The average particle size of the carrier is 80~150μm; The preparation method of the monensin premix includes the following steps: S1. Mix the monensin and the carrier to obtain mixture I; S2. Dissolve the adhesive in a water bath at 80~100℃, cool to room temperature, add the mixture I, the surfactant, the amino acid chelated trace elements, the vitamin E, the ascorbate palmitate and the coenzyme Q10, stir and mix to obtain mixture II; S3. Homogenize mixture II to obtain an intermediate product; S4. The intermediate product is made into granules by spray drying, which is the monensin premix.

2. A method for preparing the monensin premix according to claim 1, characterized in that, Includes the following steps: S1. Mix the monensin and the carrier to obtain mixture I; S2. Dissolve the adhesive in a water bath at 80~100℃, cool to room temperature, add the mixture I, the surfactant, the amino acid chelated trace elements, the vitamin E, the ascorbate palmitate and the coenzyme Q10, stir and mix to obtain mixture II; S3. Homogenize mixture II to obtain an intermediate product; S4. The intermediate product is made into granules by spray drying, which is the monensin premix.

3. The method for preparing monensin premix according to claim 2, characterized in that, In step S2, the stirring speed is 100~200 rpm and the stirring time is 30~60 min.

4. The method for preparing monensin premix according to claim 2, characterized in that, In step S3, the homogenization process is carried out at a rotation speed of 500-1500 rpm for 15-30 min.

5. The method for preparing monensin premix according to claim 2, characterized in that, In step S4, the spray drying conditions are as follows: inlet air temperature 120~150℃, drying temperature 70~90℃, outlet air temperature 50~70℃, and ventilation volume 100~600m³. 3 / h.

Images